Alzamend Neuro (ALZN) Fundamental Analysis: Revenue, Earnings & Valuation

5.28 / 10

Netural

ALZN's fundamental score of 5.3/10 indicates moderate quality. Key positives include a solid interest-coverage ratio of 42.48 and robust year-over-year revenue growth (64.40% operating revenue). However, an elevated days-sales-outstanding value of 313.91 raises collection-risk concerns. These mixed metrics result in a neutral fundamental rating.

Analysis Checks(9/10)

Revenue-MV

Value0.16

Score3/3

Weight17.30%

1M Return10.54%

Total operating revenue (YoY growth rate %)

Value45.97

Score2/3

Weight1.48%

1M Return1.11%

Days sales outstanding

Value313.91

Score1/3

Weight-1.90%

1M Return-1.57%

Profit-MV

Value0.44

Score2/3

Weight13.79%

1M Return8.45%

Net income-Revenue

Value0.15

Score2/3

Weight13.81%

1M Return8.45%

PB-ROE

Value1.56

Score2/3

Weight17.20%

1M Return9.14%

Interest coverage ratio (EBIT / Interest expense) (%)

Value42.48

Score2/3

Weight-1.38%

1M Return-1.11%

Operating revenue (YoY growth rate %)

Value64.40

Score2/3

Weight0.57%

1M Return0.43%

Asset-MV

Value-2.16

Score3/3

Weight25.57%

1M Return13.15%

Cash-MV

Value0.14

Score2/3

Weight13.56%

1M Return8.41%

Is ALZN fundamentally strong?

ALZN scores 5.28/10 on fundamentals and holds a Fair valuation at present. Backed by its -88.79% ROE, 0.00% net margin, -1.17 P/E ratio, 1.72 P/B ratio, and 95.07% earnings growth, these metrics solidify its Netural investment rating.